| Title: |
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer |
| Authors: |
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B; HERO Study Investigators |
| Contributors: |
kirurgia, Surgery; tyks, vsshp, tyks, varha; 1.2.246.10.2458963.20.97295082107 |
| Publisher Information: |
United States; Yhdysvallat (USA); US |
| Publication Year: |
2025 |
| Collection: |
University of Turku: UTUPub / Turun yliopisto |
| Description: |
BACKGROUND Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known. METHODS In this phase 3 trial, we randomly assigned patients with advanced prostate cancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels ( |
| Document Type: |
other/unknown material |
| Language: |
English |
| Relation: |
382; New England Journal of Medicine; 23; https://www.utupub.fi/handle/10024/192504 |
| DOI: |
10.1056/NEJMoa2004325 |
| Availability: |
https://www.utupub.fi/handle/10024/192504; https://www.nejm.org/doi/10.1056/NEJMoa2004325 |
| Accession Number: |
edsbas.2FFCAD27 |
| Database: |
BASE |